• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Axogen Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders (Amendment)

    6/7/24 9:15:01 PM ET
    $AXGN
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $AXGN alert in real time by email
    8-K/A
    true 0000805928 0000805928 2024-06-04 2024-06-04

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    Form 8-K/A

    (Amendment No. 1)

     

     

    Current Report

    Pursuant to Section 13 or 15(d)

    of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): June 4, 2024

     

     

    AXOGEN, INC.

    (Exact Name of Registrant as Specified in Charter)

     

     

     

    Minnesota   001-36046   41-1301878

    (State or Other Jurisdiction of

    Incorporation or Organization)

     

    (Commission

    File Number)

      (I.R.S. Employer
    Identification No.)

     

    13631 Progress Boulevard, Suite 400 Alachua, Florida   32615
    (Address of principal executive offices)   (Zip Code)

    (386) 462-6800

    (Registrant’s telephone number, including area code)

    N/A

    (Former Name or Former Address, if Changed Since Last Report)

     

     

    Check the appropriate box if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

     

    ☐

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e- 4(c))

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class

     

    Trading
    Symbol(s)

     

    Name of exchange

    on which registered

    Common Stock, $0.01 par value   AXGN   The Nasdaq Stock Market

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     


    Explanatory Note

    This Amendment No. 1 to the Current Report on Form 8-K amends Item 5.07 of the current Report on Form 8-K filed on June 7, 2024 (the “Original Form 8-K”) solely to correct typographical errors. No other changes have been made to the Original Form 8-K.

    Item 5.07. Submission of Matters to a Vote of Security Holders.

    On June 5, 2024, the Company held the Annual Meeting, at which a total of 36,494,777 shares of common stock of the Company, out of a total 43,704,574 shares of common stock outstanding and entitled to vote as of April 19, 2024, the record date, were present in person or represented by proxies. The Company’s shareholders voted on four proposals at the Annual Meeting. The proposals are described in detail in the proxy statement for the Annual Meeting that the Company filed with the Securities and Exchange Commission on April 24, 2024. The results of voting on the four proposals, including the final vote tabulations, are set forth below.

    Proposal 1: Election of Directors

    Nine directors were elected to the Board to serve for a one-year term until the 2025 annual meeting of shareholders. The results of the election were as follows:

     

    Name

     

    For

     

    Withheld

     

    Broker Non-Votes

    Karen Zaderej

      28,921,209   3,303,256   4,270,312

    Amy Wendell

      25,806,366   6,418,099   4.270,312

    William Burke

      26,910,619   5,313,846   4,270,312

    John H. Johnson

      26,776,603   5,447,862   4.270,312

    Alan Levine

      28,084,610   4,139,855   4,270,312

    Guido Neels

      27,010,948   5,213,517   4.270,312

    Paul Thomas

      27,737,898   4,486,567   4,270,312

    Joseph Tyndall, MD MPH, FACEP

      28,145,517   4,078,948   4.270,312

    Kathy Weiler

      27,471,121   4,753,344   4,270,312

    Proposal 2:Ratification of Appointment of Independent Auditors

    The Audit Committee’s selection of Deloitte & Touche LLP as the Company’s registered independent public accounting firm for the fiscal year ending December 31, 2024 was ratified. The results of the vote were as follows:

     

    For

     

    Against

     

    Abstentions

     

    Broker Non-Votes

    35,220,045   1,254,727   20,005   —

    Proposal 3: Compensation of the Named Executive Officers

    The advisory (non-binding) vote on the executive compensation of the Company’s named executive officers was approved. The results were as follows:

     

    For

     

    Against

     

    Abstentions

     

    Broker Non-Votes

    22,655,899   9,494,316   74,250   4,270,312

    Proposal 4: Amendment and Restatement of the Axogen, Inc. 2019 Long-Term Incentive Plan

    The Axogen, Inc. Third Amended and Restated 2019 Long-Term Incentive Plan to increase the number of shares reserved for issuance thereunder from 8,000,000 to 10,500,000 was approved. The results of the vote were as follows:

     

    For

     

    Against

     

    Abstentions

     

    Broker Non-Votes

    22,846,399   9,336,789   41,277   4,270,312


    Item 9.01. Financial Statements and Exhibits.

    (d) Exhibits

     

    Exhibit No.

      

    Description

    104    Cover Page Interactive Data File (embedded within the Inline XBRL document)


    SIGNATURES

    Pursuant to the requirements of the Exchange Act, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

        AXOGEN, INC.
    Date: June 7, 2024     By:  

    /s/ Marc Began

          Marc Began
          Executive Vice President, General Counsel and Chief Compliance Officer
    Get the next $AXGN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AXGN

    DatePrice TargetRatingAnalyst
    2/19/2026$40.00Overweight
    Wells Fargo
    12/1/2025$40.00Outperform
    Mizuho
    3/17/2025$30.00Buy
    Lake Street
    7/1/2024$13.00Outperform
    Raymond James
    11/11/2022$15.00Buy
    Jefferies
    5/9/2022$10.00 → $15.00Hold → Buy
    Canaccord Genuity
    3/11/2022$21.00Overweight
    Cantor Fitzgerald
    11/4/2021$25.00 → $20.00Market Outperform
    JMP Securities
    More analyst ratings

    $AXGN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Devinney Erick Wayne

    4 - Axogen, Inc. (0000805928) (Issuer)

    3/18/26 4:11:17 PM ET
    $AXGN
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 4 filed by Hartley Lindsey Marie

    4 - Axogen, Inc. (0000805928) (Issuer)

    3/18/26 4:10:01 PM ET
    $AXGN
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Chief Marketing Officer Kemp Jens was granted 50,670 shares and covered exercise/tax liability with 18,366 shares, increasing direct ownership by 73% to 76,451 units (SEC Form 4)

    4 - Axogen, Inc. (0000805928) (Issuer)

    3/2/26 6:16:56 PM ET
    $AXGN
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $AXGN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Axogen, Inc. Reports Fourth Quarter and Full-Year 2025 Financial Results

    ALACHUA, Fla. and TAMPA, Fla., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today reported financial results and business highlights for the fourth quarter and full-year ended December 31, 2025. Fourth Quarter Financial Results Fourth quarter 2025 revenue was $59.9 million, a 21.3% increase compared to the fourth quarter 2024 revenue, and a 0.3% decrease over the third quarter 2025 revenue. Fourth quarter 2025 gross margin was 74.1%, down from 76.1% for the fourth quarter of 2024, and down from 76.6% in the third quarter of 2025. Gross margin refl

    2/24/26 7:00:00 AM ET
    $AXGN
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Axogen, Inc. to Participate in Multiple Upcoming Investor Conferences

    ALACHUA, Fla. and TAMPA, Fla., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today announced that management is scheduled to participate in three upcoming investor conferences: Raymond James 47th Annual Institutional Investors ConferenceParticipation: Presentation and 1x1 investor meetingsDate/Time: Presentation Tuesday, March 3, 2026, 3:25 PM ETWebcast Link: Raymond James/Axogen Presentation Leerink Global Healthcare ConferenceParticipation: Fireside Chat and 1x1 investor meetingsDate/Time: Fireside Chat Monday, March 9, 2026, 1:00 PM ETWebcast Link

    2/17/26 7:00:00 AM ET
    $AXGN
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Axogen, Inc. to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026

    ALACHUA, Fla. and TAMPA, Fla., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today announced that it will release financial results for the fourth quarter and full year 2025 on Tuesday, February 24, 2026. Axogen management will host an investment-community conference call and webcast at 8:00 a.m. ET following the release. Investors interested in participating in the conference call by phone may dial toll-free at (877) 407-0993 or use the direct dial-in number at (201) 689-8795. A live webcast, an archived replay, and presentation slides from the event

    2/10/26 7:00:00 AM ET
    $AXGN
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $AXGN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Wells Fargo initiated coverage on AxoGen with a new price target

    Wells Fargo initiated coverage of AxoGen with a rating of Overweight and set a new price target of $40.00

    2/19/26 7:50:49 AM ET
    $AXGN
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Mizuho initiated coverage on AxoGen with a new price target

    Mizuho initiated coverage of AxoGen with a rating of Outperform and set a new price target of $40.00

    12/1/25 8:24:55 AM ET
    $AXGN
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Lake Street initiated coverage on AxoGen with a new price target

    Lake Street initiated coverage of AxoGen with a rating of Buy and set a new price target of $30.00

    3/17/25 8:23:19 AM ET
    $AXGN
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $AXGN
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Axogen Inc.

    SCHEDULE 13G/A - Axogen, Inc. (0000805928) (Subject)

    3/26/26 4:11:25 PM ET
    $AXGN
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 10-K filed by Axogen Inc.

    10-K - Axogen, Inc. (0000805928) (Filer)

    2/24/26 4:24:04 PM ET
    $AXGN
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Axogen Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Axogen, Inc. (0000805928) (Filer)

    2/24/26 7:02:30 AM ET
    $AXGN
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $AXGN
    Financials

    Live finance-specific insights

    View All

    Axogen, Inc. to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026

    ALACHUA, Fla. and TAMPA, Fla., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today announced that it will release financial results for the fourth quarter and full year 2025 on Tuesday, February 24, 2026. Axogen management will host an investment-community conference call and webcast at 8:00 a.m. ET following the release. Investors interested in participating in the conference call by phone may dial toll-free at (877) 407-0993 or use the direct dial-in number at (201) 689-8795. A live webcast, an archived replay, and presentation slides from the event

    2/10/26 7:00:00 AM ET
    $AXGN
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Axogen, Inc. Reports Third Quarter 2025 Financial Results

    ALACHUA, Fla. and TAMPA, Fla., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today reported financial results and business highlights for the third quarter ended September 30, 2025. Third Quarter Financial Results Third quarter revenue was $60.1 million, a 23.5% increase compared to the third quarter of 2024, and a 6.0% increase over the second quarter of 2025.For the third quarter of 2025, gross margin was 76.6%, up from 74.9% for the third quarter of 2024, and up from 74.2% in the second quarter of 2025.Net income for the quarter was $0.7 million,

    10/29/25 7:00:00 AM ET
    $AXGN
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Axogen, Inc. to Report 2025 Third Quarter Financial Results on October 29, 2025

    ALACHUA, Fla. and TAMPA, Fla., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today announced that it will report 2025 third quarter financial results on Wednesday, October 29, 2025, before the market opens. Axogen management will host an investment-community conference call and webcast at 8 a.m. ET following the release. Investors interested in participating in the conference call by phone may do so by dialing toll free at (877) 407-0993 or use the direct dial-in number at (201) 689-8795. A live webcast, archived replay, and presentation slides of t

    10/15/25 7:00:00 AM ET
    $AXGN
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $AXGN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Axogen Inc.

    SC 13G/A - Axogen, Inc. (0000805928) (Subject)

    11/14/24 3:31:14 PM ET
    $AXGN
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SC 13G filed by Axogen Inc.

    SC 13G - Axogen, Inc. (0000805928) (Subject)

    11/7/24 4:34:48 PM ET
    $AXGN
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Amendment: SEC Form SC 13G/A filed by Axogen Inc.

    SC 13G/A - Axogen, Inc. (0000805928) (Subject)

    9/10/24 4:00:03 PM ET
    $AXGN
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $AXGN
    Leadership Updates

    Live Leadership Updates

    View All

    Axogen Announces Chief Financial Officer Transition

    ALACHUA, Fla. and TAMPA, Fla., May 08, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced the appointment of Lindsey Hartley, CPA, as Chief Financial Officer, effective May 12, 2025. Ms. Hartley, who currently serves as Vice President, Corporate Controller at Axogen, will succeed Nir Naor, who is departing to pursue other opportunities. Mr. Naor will remain with the Company in an advisory capacity until July 1, 2025, to ensure a smooth transition. "I want to express my sincere gratitude to Nir for his service to Axogen," said Michael Dale, President, Chief Executive O

    5/8/25 7:00:00 AM ET
    $AXGN
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Axogen Announces Appointment of Rick Ditto as Vice President, Global Health Economics, Reimbursement & Policy, and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

    ALACHUA, Fla. and TAMPA, Fla., March 24, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced the appointment of Rick Ditto as Vice President, Global Health Economics, Reimbursement & Policy. Mr. Ditto will report to Michael Dale, President, and Chief Executive Officer, and will lead the development of the coverage and reimbursement-related strategies required to support Axogen's mission to establish restoration of peripheral nerve function as an expected standard of care. Mr. Ditto brings over 15 years of leadership experience in the medical device industry, with a pr

    3/24/25 8:00:00 AM ET
    $AXGN
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Axogen Announces Appointment of Jesse Bishop as Vice President of Regulatory Affairs and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

    ALACHUA, Fla. and TAMPA, Fla., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced the appointment of Jesse Bishop as Vice President of Regulatory Affairs. Mr. Bishop will report to Michael Dale, President, and Chief Executive Officer, and will lead the development and execution of domestic and international regulatory strategies to advance company objectives related to new product development, market approval, market development and other regulatory initiatives. Mr. Bishop will oversee all facets of Axogen's regulatory affairs, maintenance of Axogen product

    2/3/25 8:00:00 AM ET
    $AXGN
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care